Brooke Story’s Appointment Marks a New Era for PolyPid
PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company dedicated to enhancing surgical results, has recently appointed Brooke Story as its new Chairman of the Board of Directors. This strategic move, effective December 11, 2025, represents a significant turning point in the company's trajectory.
Leading with Experience in MedTech
Brooke Story brings a wealth of experience to PolyPid, having spent more than 25 years in the MedTech sector. Her previous roles include key positions at major companies such as BD (Becton, Dickinson and Company) and Medtronic PLC, where she was deeply involved in surgical innovations and infection prevention technologies.
Pioneering Surgical Solutions
As the former Worldwide President of BD's Surgery division, Ms. Story oversaw global strategies and managed a diverse portfolio including hernia repair and tissue repair products. Her expertise will be crucial as PolyPid seeks to leverage its clinical achievements and transform them into commercial successes.
Commitment to Surgical Infection Prevention
Ms. Story expressed her enthusiasm for joining PolyPid, positioning it at a critical point in its growth journey. She emphasizes the potential to utilize the company’s innovative delivery platform and address pressing needs in surgical infection prevention, which could significantly enhance patient outcomes.
PolyPid’s Innovative Technologies
At the heart of PolyPid's mission is its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology. This advanced system enables targeted delivery of therapeutics, providing controlled, prolonged drug release for periods ranging from several days to months. The company’s lead product, D-PLEX100, is under development for the prevention of surgical site infections, with an expected New Drug Application (NDA) submission anticipated in early 2026.
Strategic Leadership and Vision
Throughout her career, Ms. Story has not only led significant corporate strategies but has also been pivotal in mergers, acquisitions, and licensing agreements. Her current role as BD's Separation and Integration Lead demonstrates her capability in managing complex corporate transitions, a skill that will surely benefit her leadership at PolyPid.
A Bright Future Ahead
With Brooke Story at the helm, PolyPid is positioned to enhance its impact in the healthcare industry. The company is also diversifying its pipeline, focusing on new treatments in oncology, obesity, and diabetes, thereby expanding its reach beyond surgical applications.
Recognitions and Board Memberships
In addition to her responsibilities at PolyPid, Ms. Story serves as a non-executive director on the Board of LivaNova PLC and has previously contributed to the boards of Sigilon Therapeutics, Inc. and Avation Medical, Inc. Her academic credentials include a Bachelor’s degree in Engineering from the University of Tennessee and an MBA from the University of Michigan.
Company Information and Contact
For more information on PolyPid, you can visit their official website at http://www.polypid.com. For any inquiries, you can reach out to Ori Warshavsky at 908-858-5995 or via email at IR@Polypid.com.
Frequently Asked Questions
Who is Brooke Story?
Brooke Story is a seasoned leader in the MedTech industry with over 25 years of experience, recently appointed as the Chairman of PolyPid.
What is PolyPid's main focus?
PolyPid focuses on improving surgical outcomes through its innovative drug delivery systems, particularly targeting infection prevention in surgical settings.
What technologies does PolyPid utilize?
PolyPid utilizes its proprietary PLEX technology for controlled and prolonged therapeutic delivery, enhancing the effectiveness of treatments and improving patient outcomes.
What are the future plans of PolyPid?
PolyPid aims to submit its NDA for D-PLEX100 in early 2026 and expand its product pipeline into areas like oncology and diabetes.
How can investors contact PolyPid?
Investors can reach out to PolyPid's Investor Relations via email at polypid@arxhq.com.
